# Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

> **NCT05688215** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 56 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Core Biopsy
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Leucovorin Calcium
- **DRUG:** Oxaliplatin
- **DRUG:** Quemliclustat
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT05688215
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-03-02
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05688215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05688215, "Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05688215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*